Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.69)
# 3,896
Out of 4,829 analysts
48
Total ratings
100%
Success rate
16%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $25.17 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $4.56 | - | 4 | Apr 1, 2025 | |
| GLYC GlycoMimetics | Initiates: Overweight | n/a | $0.26 | - | 1 | Mar 21, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $5.22 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $14.26 | -8.77% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $1.33 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $7.57 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $37.45 | - | 4 | Feb 19, 2025 | |
| CDTX Cidara Therapeutics | Assumes: Overweight | n/a | $19.36 | - | 1 | Jan 27, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $60.50 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.16 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.28 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $29.48 | +225.64% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.38 | - | 2 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $29.44 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $124.39 | +134.75% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $438.01 | -15.53% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.52 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.29 | - | 1 | May 30, 2017 |
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.17
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.56
Upside: -
GlycoMimetics
Mar 21, 2025
Initiates: Overweight
Price Target: n/a
Current: $0.26
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.22
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $14.26
Upside: -8.77%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.33
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.57
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $37.45
Upside: -
Cidara Therapeutics
Jan 27, 2025
Assumes: Overweight
Price Target: n/a
Current: $19.36
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $60.50
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.16
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.28
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $29.48
Upside: +225.64%
Sep 16, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.38
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.44
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $124.39
Upside: +134.75%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $438.01
Upside: -15.53%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.52
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.29
Upside: -